ESMO 2022 | Lung cancer molecular testing in the UK

Riyaz Shah, BSc(Hons), MBBS, FRCP, PhD, Kent Oncology Centre, Maidestone, UK, provides a comprehensive overview of lung cancer molecular testing in the United Kingdom, and highlights challenges in implementing precision medicine in the advent of novel molecularly-targeting agents in non-small cell lung cancer. Dr Shah also discusses the potential of liquid biopsies to guide treatment decisions. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.